loading...| Preferred Name |
Ruxolitinib |
|
| Synonyms |
Oral JAK Inhibitor INCB18424 RUXOLITINIB (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Ruxolitinib INCB-18424 INCB18424 |
|
| Definitions |
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C77888 |
|
| Accepted_Therapeutic_Use_For |
steroid-refractory acute graft-versus-host disease (GVHD) |
|
| CAS_Registry |
941678-49-5 |
|
| Chemical_Formula |
C17H18N6 |
|
| code |
C77888 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc |
|
| DEFINITION |
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies. |
|
| Display_Name |
Ruxolitinib |
|
| FDA_UNII_Code |
82S8X8XX8H |
|
| FULL_SYN |
Oral JAK Inhibitor INCB18424 RUXOLITINIB (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile Ruxolitinib INCB-18424 INCB18424 |
|
| Has_Salt_Form | ||
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Ruxolitinib |
|
| Legacy Concept Name |
Oral_JAK_Inhibitor_INCB18424 |
|
| Maps_To |
Ruxolitinib |
|
| Preferred_Name |
Ruxolitinib |
|
| prefixIRI |
Thesaurus:C77888 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C2715577 |
|
| subClassOf |